News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Aerocrine: Interim Report January - June 2011
July 22, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Sales for routine clinical use in the US continue to show a positive trend. Aerocrine (STO:AEROB) secured the company's largest single order to date, valued at SEK 5.5 million.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Psychedelics
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
July 16, 2026
·
2 min read
·
Tristan Manalac
IPO
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
July 16, 2026
·
4 min read
·
Tristan Manalac
Psychedelics
J&J sees Spravato sales surge as psychedelic competitors loom
July 16, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
July 16, 2026
·
6 min read
·
Angela Gabriel
